News

Kutxa Fundazioa, the Basque Government, and the Spanish Government are driving Oncomatryx’s transformation into a biopharmaceutical company

by

The Spanish Government is contributing 24.3 million euros through the Ministry of Science, Innovation, and Universities, reinforcing its commitment to technological innovation for health. Kutxa Fundazioa leads the Basque investment with 15 million euros, alongside a 10.5 million euro contribution from the Basque Government and Ekarpen and 2 million euros from BBK, bringing the total … Read more

Oncomatryx receives the Banco Santander and Spanish Chamber of Commerce Innovation Award from the King

by

Banco Santander and the Spanish Chamber of Commerce present the 2025 National SME of the Year Award Thursday, February 19, 2026. Oncomatryx has received the Innovation and Digitalization Award at the 9th edition of the National SME of the Year Awards, organized by Banco Santander and the Spanish Chamber of Commerce. King Felipe VI presented … Read more

A Spanish drug offers new hope to patients with metastatic cancer

by

Laureano Simón, CEO of Oncomatryx, explains on “La Ventana” how this new treatment could reverse metastasis. A Spanish drug offers new hope to patients with metastatic cancer There is still no cure for cancer, but investment in research and technology is making it possible for many cancer patients to enjoy a better quality of life … Read more

Oncomatryx Biopharma Awarded Prestigious EIC Accelerator Funding to Advance Groundbreaking ADCs

by

BILBAO, Spain— Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU’s Horizon Europe 2021-2027 Research and Innovation Program. As part of this highly competitive program, Oncomatryx will receive €2.5 million in grant funding, along with a €10 million equity … Read more

ONCOMATRYX raises €25 Million to foster OMTX705 Clinical Trials

by

ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnologico e Innovacion (CDTI). … Read more

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment

by

Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload.The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. … Read more

Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors

by

After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, … Read more

Oncomatryx Announces a €15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment

by

Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment – targeted ADCs. OMTX705, the Crown Jewel, has already proven high antitumor efficacy and unbeatable ADC safety in murine and non-human primate models. Phase I clinical trials in patients suffering metastatic solid tumors will … Read more